For the first time, Servier’s original brand medicines will be “Made in Vietnam.”
On May 27 at the French Embassy in Hanoi, Servier and Ampharco signed a technology transfer agreement, marking Vietnam as a manufacturing site for a portfolio of Servier’s strategic original brand medicines. These high-value products are widely used to treat chronic conditions such as diabetes, coronary artery disease, and venous insufficiency.
Under the agreement, the manufacturing facility will be located in the Nhon Trach Industrial Park, Dong Nai Province, and invested by Ampharco. The plant was awarded EU-GMP certification in March 2025, authorizing production to Europe’s highest quality standards. With technical support and supervision from Servier, production is slated to begin in 2026 at a scale covering roughly 50% of Servier’s original brand medicines distributed in Vietnam.
Servier, France’s leading independent pharmaceutical group, has transferred the technology to produce original brand medicines to Ampharco.
The first products are expected to complete registration and reach the market by late 2026, following evaluation and marketing authorization. This will be the first time Servier’s original brand medicines in cardiovascular, diabetes, and venous disease are manufactured in Vietnam.
It is uncommon for a global pharmaceutical group to select Vietnam as a production site for original brand medicines. According to Mr. Serge Nicollerat, General Director of Servier Vietnam, this milestone is the result of more than seven years of collaboration, reflecting confidence in domestic manufacturing capability, stable policy, and Vietnam’s long-term pharmaceutical development strategy.
The agreement goes beyond contract manufacturing. It constitutes a substantive transfer—covering technology, production processes, quality management, and training of technical staff. Ampharco will not merely produce, but also operate and control the entire line in line with international standards.
Ampharco representatives noted that, with EU-GMP-compliant capacity, the plant will serve the domestic market and target exports in the near future. Localized production of original brand medicines will significantly reduce logistics, import, and storage costs, improving access for Vietnamese patients.
Aligned with the national strategy through 2045
Vietnam’s Pharmaceutical Development Strategy to 2030, with a vision to 2045, targets building a regional hub for pharmaceutical innovation, with 80% domestic medicine production, including at least 100 original brand medicines produced via technology transfer.
Ampharco, with EU-GMP certification, meets the highest pharmaceutical manufacturing standards applied in Europe.
According to the Ministry of Health, Vietnam has around 250 pharmaceutical manufacturing plants, but only a small share meets EU-GMP—a necessary condition for receiving technology transfers for original brand medicine production. Ampharco is among the few that are able to meet this bar, thanks to systematic investment in infrastructure, talent, and strict adherence to international quality systems.
Servier’s decision is not only a business strategy; it also signals a positive investment climate, growing industrial capability, and policy stability. It offers Vietnam an opportunity to strengthen its position in global pharmaceutical supply chains and attract additional multinational investment to the region.
Most importantly, manufacturing original brand medicines in Vietnam delivers direct benefits to patients. Instead of relying on imported drugs, patients can access EU-standard therapies produced domestically, at reasonable cost and with a more stable supply.
With EU-GMP quality controls and Servier’s close supervision, locally manufactured products will match the quality of those produced in Europe, strengthening confidence in domestically made medicines.
Servier’s move to manufacture original brand medicines in Vietnam marks a new phase for the country’s pharmaceutical sector—from being primarily a consumer to becoming a holder of advanced technology.
As multinationals move beyond selling into Vietnam to transferring knowledge, technology, and operating capabilities, the benefits extend not only to enterprises but also to patients, the health system, and the sustainable development of the pharmaceutical industry.
Source:
https://dantri.com.vn/suc-khoe/servier-se-san-xuat-thuoc-biet-duoc-tai-viet-nam-20250605163150490.htm